Table 1 Characteristics of the studies included in the systematic review
From: The prevalence of sarcopenia in spondyloarthritis patients: a meta-analysis
Study | Country/Region | Type of study | Classification used | Assessment method for muscle mass | Correction method for muscle mass | Age (mean (SD)) (total-men-women) | BMI (mean (SD)) (total-men-women) | Disease duration (m, mean (SD)) (total-men-women) | Sample (n) (total-men-women) | Muscle mass (mean (SD)) (total-men-women) | Grip strength (mean (SD)) (total-men-women) | Physical performance (mean (SD)) (total-men-women) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aguiar 2014 [14] | Portugal/Europe | Case-control study | Lee’s equation | Measuring Tape and Skinfold Caliper | Sex, Age, and Ethnicity | 45.5 (13.4)-NA-NA | NA | 10.9 (11.6)-NA-NA | 60-29-31 AS 36-NA-NA PsA 24-NA-NA | 7.7 (1.0)-7.8 (0.9) -7.5 (1.0) | NA | NA |
Barone 2018 [15] | Italy/Europe | Cross section survey | EWGSOP for sarcopenia Other for presarcopenia | BIA 101 | Height | AS 51.6 (8.8)-NA-NA PsA 55.3 (9.1)-NA-NA | AS 24.9 (2.5)-NA-NA PsA 25.6 (3.0)-NA-NA | AS 14.5 (8.4)-NA-NA PsA 11.1 (8.1)-NA-NA | AS 22-14-8 PsA 70-32-38 | NA | NA | NA |
Barros 2012 [16] | Brazil/South American | Cohort study | Baumgartner | DXA | Height | NA | 25.7 (NA)-NA-NA | NA | 30-24-6 | NA | NA | NA |
Fitzgerald 2017 [17] | Ireland/Europe | Cross section survey | Other | BIA | Height | 50.8 (11.1)-51 (10.5) -50.4 (13.7) | 28.8 (6.3)-29 (6.9) -27.8 (3.4) | 24 (11.7)-24.5 (11.6) -22.2 (12.7) | 43-34-9 | 8.7 (1.7)-9.2 (1.6) -7.0 (0.6) | NA | NA |
Kavadichanda 2022 [18] | India/Asia | Cross section survey | AWGS | DXA | Height | SpA 38.8 (7.5)-NA-NA PsA 41.3 (9.3)-NA-NA | SpA 23.6 (NA)-NA -NA PsA 25.1 (NA)-NA-NA | NA | SpA 58-44-14 PsA 56-28-28 | Total 6.9 (1.1)-NA -NA | NA | NA |
Krajewska 2017 [19] | Poland/Europe | Case-control study | EWGSOP | BIA (InBody170) | Height | 65.6 (5.9)-NA-NA | 30.1 (5.8)-NA-NA | 11.1 (8.9)-NA-NA | 51-0-51 | 6.44 (0.72) | NA | NA |
Leite 2020 [20] | Brazil/South American | Cross section survey | Other | DXA | Height | NA | NA | NA | 96-43-53 | 7.7 (1.3)-8.54 (1.29) -6.94 (0.87) | NA | NA |
Maghraoui 2016 [21] | Morocco/Africa | Cross section survey | EWGSOP for sarcopenia Baumgartner for presarcopenia | DXA | Height | 40.9 (11.0)-NA-NA | 25.3 (4.0)-NA-NA | 9.3 (7.9)-NA-NA | 67-67-0 | 7.4 (0.8) -NA-NA | NA | NA |
Merle 2023 [2] | France/Europe | Case-control study | EWGSOP2 | DXA | Height | 47.1 (13.7)-47.0 (13.6) -47.3 (13.9) | 26.0 (5.0)-25.8 (4.8) -26.2 (5.2) | 12.2 (9.0)-11.9 (10.4) -12.6 (7.6) | 103-50-53 | 7.4 (1.3)-8.0 (1.2) -6.6 (1.0) | 28.8 (13.1)-37.1 (12.9)-20.8 (6.9) | 0.9 (0.4)-0.9 (0.4)-0.9 (0.4) |
Neto 2022 [22] | Portugal/Europe | Cross section survey | EWGSOP2 | BIA (InBody770) | Height | 37.0 (7.0)-NA-NA | 25.0 (NA)-NA-NA | 7 (3.0)-NA-NA | 27-18-9 | NA | NA | 0.8 (0.1)-NA-NA |
Paccou 2020 [23] | France/Europe | Cohort study | Baumgartner | DXA | Height | NA | NA | NA | 30-NA-NA | NA | NA | NA |
Sequeira 2013 [24] | Portugal/Europe | Case-control study | Lee’s equation | Measuring Tape and Skinfold Caliper | Sex, Age, and Ethnicity | 45.5 (13.4)-NA-NA | NA | 10.9 (11.6)-NA-NA | 60-29-31 | NA | NA | NA |
Song 2017 [25] | Sourth Korea/Asia | Cross section survey | AWGS Korea criteria | DXA | Height | NA | NA | NA | 60-60-0 | NA | NA | NA |
Soto 2023 [26] | Brazil/South merican | Diagnosis test | ASMM | DXA | Height | 49.2 (14.2)-NA-NA | NA | NA | 42-24-18 AS 35-NA-NA PsA 7-NA-NA | NA | NA | NA |
Tournadre 2017 [27] | France/Europe | Cross section survey | EWGSOP | DXA | Height | SpA 44.1 (12.0) PsA 54.6 (11.0) | SpA 28.7 (5.1) PsA 54.6 (11.0) | SpA 6.4 (9.4) PsA 5.5 (6.8) | SpA 63-NA-NA PsA 11-NA-NA | SpA 8.1 (1.6) PsA 8.0 (1.7) | NA | NA |
Younis 2021 [28] | Iraq/Asia | Cross section survey | EWGSOP | DXA | Height | 36.6 (7.7)-NA-NA | 28.4 (6.3)-NA-NA | 6.9 (5.0)-NA-NA | 50-47-3 | 8.0 (1.0)-NA-NA | 32.9 (8.3)-NA-NA | 0.9 (0.2)-NA-NA |